Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021
September 27 2021 - 7:00AM
Business Wire
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal
Phase 2/3 trial in Alzheimer’s disease and a growing pipeline of
therapeutics for degenerative diseases, today announced that it
will participate at the upcoming 14th Clinical Trials on
Alzheimer's Disease (CTAD 2021) conference scheduled for November
9-12, 2021, in Boston, Massachusetts, as well as virtually.
Cortexyme will present results from its Phase 2/3 GAIN Trial
evaluating the efficacy of its lead small molecule atuzaginstat in
643 mild to moderate Alzheimer’s patients. Cortexyme expects to
announce top-line results in advance of its scientific presentation
at CTAD 2021. Results of the GAIN Trial’s Phase 2 periodontal
disease REPAIR sub-study also are expected to be announced by
mid-November.
About Cortexyme
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage
biopharmaceutical company pioneering upstream therapeutic
approaches designed to improve the lives of patients diagnosed with
Alzheimer’s and other degenerative diseases. The company is
advancing its disease-modifying therapy in mild to moderate
Alzheimer's disease, in addition to growing a proprietary pipeline
of first-in-class small molecule therapeutics for Parkinson’s
disease, periodontitis, coronavirus and other diseases with high
unmet clinical need. Cortexyme’s lead program targets a specific,
infectious pathogen called P. gingivalis found in the brain and
other organs and tied to degeneration and inflammation in humans
and animal models. The company’s causation evidence for Alzheimer’s
disease and the mechanism of its novel therapeutic has been
independently replicated and confirmed by multiple laboratories
around the world, as well as published in peer-reviewed scientific
journals. To learn more about Cortexyme, visit www.cortexyme.com or
follow @Cortexyme on Twitter.
Forward-Looking Statements
Statements in this news release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this news
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast,” “potential” or other similar
words. Examples of forward-looking statements include, among
others, statements Cortexyme makes regarding the sufficiency of its
cash position to fund its operations; its business plans, strategy,
timeline, prospects, and milestone expectations; the timing and
success of the company’s clinical trials and related data,
including with respect to the GAIN and REPAIR Trials, as well as
enabling and human studies of COR588; the potential of atuzaginstat
to treat Alzheimer’s disease, periodontal disease, and other
potential indications; the potential of COR803 to treat coronavirus
infections; the timing of announcements and updates relating to its
clinical trials and related data; the potential therapeutic
benefits, safety and efficacy of the company’s product candidate or
library of compounds and statements about its ability to obtain,
and the timing relating to, regulatory submissions and approvals
with respect to the company’s drug product candidate.
Forward-looking statements are based on Cortexyme’s current
expectations and are subject to inherent uncertainties, risks, and
assumptions that are difficult to predict and could cause actual
results to differ materially from what the company expects.
Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Factors that could cause actual results to differ include, but are
not limited to, the risks and uncertainties described in the
section titled “Risk Factors” in Cortexyme’s Annual Report on Form
10-K filed with the Securities and Exchange Commission (SEC) on
March 1, 2021, its Quarterly Report on Form 10-Q filed with the SEC
on August 6, 2021, and other reports as filed with the SEC.
Forward-looking statements contained in this news release are made
as of this date, and Cortexyme undertakes no duty to update such
information except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210927005237/en/
Cortexyme Contact: Stacy Roughan Cortexyme, Inc. Vice
President, Corporate Communications & Investor Relations
ir@cortexyme.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Apr 2023 to Apr 2024